FNAIT RESEARCH MATTERS TO ALL OF US

The image depicted contains models and is being used for illustrative purposes only.

Are you pregnant with a baby at risk for fetal and neonatal alloimmune thrombocytopenia (FNAIT)?

A clinical research study is now enrolling eligible participants.

What is the purpose of this study?

The purpose of this study is to assess the safety and efficacy of an investigational medication in pregnancies at risk for FNAIT.

Am I able to participate?

The **FREESIA-3** study is enrolling participants who:

- Are 18 to 45 years of age
- Are pregnant with an estimated gestational age (based on ultrasound) from Week 8 to $18^{6/7}$
- Have a history of at least 1 prior pregnancy with FNAIT

Additional criteria will apply.

What's involved with participating in the FREESIA-3 study?

Study participants will receive either the investigational medication or the standard of care study medication. Neither study medication (investigational or standard of care) is approved to treat FNAIT.

There is an 80% (4 in 5) chance of receiving the investigational medication. There is a 20% (1 in 5) chance of receiving the standard of care study medication. Some participants who are receiving the standard of care study medication may receive an additional study medication (a tablet that is taken by mouth).

Participants will receive their study medication through weekly intravenous (IV) infusions until delivery. Participants and the study doctor/staff will know which study medication is being given.

Participants will receive about 23 to 28 IV infusions.

After giving birth, participants will have a follow-up period of about 6 months. Additionally, participants' babies will have a follow-up period of about 2 years. During this time, participants will have 3 study clinic visits and their babies will have 6 study clinic visits.

Total participation in this study will last approximately 3 years. This includes screening for eligibility, study medication dosing, and follow-up.

Does participating in this study cost anything?

All participants will be reimbursed for study-required travel and receive study-required medical care at no cost. Study medication will be provided to you at no cost. You will be responsible for other medical care and medications that are not part of the study.

What can I expect at my first visit to the study clinic?

If you join the study and sign the informed consent form, you will attend a screening visit. At this visit, you will undergo tests and procedures to determine if you can be in this study.

You can leave the study at any time and for any reason. Even if you begin the study, you can stop at any point.

What if my condition worsens?

You and your baby will be closely monitored during this study. You will both receive the same level of care no matter which study medication you receive.

If your or your baby's health changes in this study, the study doctor/staff will tell you immediately. You should also tell the study doctor/staff about any health changes you or your baby experience. Your and your baby's physical health and well-being are the most important part of this study.

Where do I find more information?

For more information about the FREESIA-3 study, please contact:

Janssen Research & Development, LLC,
a Johnson & Johnson Company
80202135FNAIT3003-ENG05 INT-3
Version 2.0, 27Feb2025